Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC in Early Phase Schizophrenia Spectrum Psychosis
NCT01354132Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- May 2011
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acetylcysteine in schizophrenia, schizophreniform disorder and schizoaffective disorder, sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS at 6 months. Started May 2011; status: completed.
02
Drugs
acetylcysteine
03
Conditions
schizophreniaschizophreniform disorderschizoaffective disorder
Beyond the preview
Go deeper on NCT01354132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01354132.